Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Ulsan University College of Medicine, Seoul, Republic of Korea.
J Autoimmun. 2021 Aug;122:102681. doi: 10.1016/j.jaut.2021.102681. Epub 2021 Jun 15.
Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.
腺病毒 COVID-19 载体疫苗接种后有报道称发生了脑静脉血栓形成 (CVT) 事件。本研究旨在比较两种腺病毒载体疫苗，Ad26.COV.2.S（Janssen/Johnson & Johnson）和 ChAdOx1 nCoV-19（Astra-Zeneca），引起的疫苗诱导的血栓性血小板减少症 (VITT) 的临床表现和病程。我们发现，Ad26.COV.2.S 疫苗接种后的 CVT 表现较晚，与 ChAdOx1 nCoV-19 给药后的 CVT 具有相似的症状，尽管血栓形成和颅内出血更多，D-二聚体和 aPTT 水平较低，但死亡率相似。这些发现可以帮助指导 COVID-19 疫苗接种后 CVT 的临床评估和管理。
Zotero 插件